BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] surged by $0.04 during the normal trading session on Monday and reaching a high of $4.47 during the day while it closed the day at $4.45. The company report on November 13, 2020 that BioCryst Presents Data Showing Sustained Attack Rate Reductions, Improved Patient Satisfaction and Quality of Life for HAE Patients Taking Berotralstat in APeX-2 Trial.
—Data presented at 2020 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)—.
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) presented new clinical data that further evaluates the attack rate reductions, patient satisfaction and quality of life of hereditary angioedema (HAE) patients in the APeX-2 trial over 48 weeks. Berotralstat is an investigational treatment for the prevention of attacks in patients with HAE.
BioCryst Pharmaceuticals Inc. stock has also gained 14.69% of its value over the past 7 days. However, BCRX stock has declined by -1.33% in the 3 months of the year. Over the past six months meanwhile, it has lost -12.75% and gained 28.99% year-on date.
The market cap for BCRX stock reached $757.21 million, with 176.52 million shares outstanding and 175.07 million shares in the current float. Compared to the average trading volume of 5.01M shares, BCRX reached a trading volume of 3922018 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about BioCryst Pharmaceuticals Inc. [BCRX]:
JP Morgan have made an estimate for BioCryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on September 29, 2020. The new note on the price target was released on June 17, 2020, representing the official price target for BioCryst Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $7, while Barclays analysts kept a Overweight rating on BCRX stock. On November 15, 2019, analysts decreased their price target for BCRX shares from 5 to 4.
The Average True Range (ATR) for BioCryst Pharmaceuticals Inc. is set at 0.23, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 14.15. The Price to Book ratio for the last quarter was 23.42, with the Price to Cash per share for the same quarter was set at 0.84.
BCRX stock trade performance evaluation
BioCryst Pharmaceuticals Inc. [BCRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.69. With this latest performance, BCRX shares gained by 15.73% in over the last four-week period, additionally sinking by -12.75% over the last 6 months – not to mention a rise of 154.29% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 62.75, with the RSI for the last a single of trading hit 68.97, and the three-weeks RSI is set at 60.19 for BioCryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 3.83, while it was recorded at 4.29 for the last single week of trading, and 3.79 for the last 200 days.
BioCryst Pharmaceuticals Inc. [BCRX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and BioCryst Pharmaceuticals Inc. [BCRX] shares currently have an operating margin of -203.66 and a Gross Margin at +91.60. BioCryst Pharmaceuticals Inc.’s Net Margin is presently recorded at -222.99.
Return on Total Capital for BCRX is now -85.02, given the latest momentum, and Return on Invested Capital for the company is -135.90. Return on Equity for this stock declined to -248.94, with Return on Assets sitting at -67.61. When it comes to the capital structure of this company, BioCryst Pharmaceuticals Inc. [BCRX] has a Total Debt to Total Equity ratio set at 221.30. Additionally, BCRX Total Debt to Total Capital is recorded at 68.88, with Total Debt to Total Assets ending up at 48.30. Long-Term Debt to Equity for the company is recorded at 116.84, with the Long-Term Debt to Total Capital now at 36.37.
Reflecting on the efficiency of the workforce at the company, BioCryst Pharmaceuticals Inc. [BCRX] managed to generate an average of -$777,836 per employee. Receivables Turnover for the company is 3.69 with a Total Asset Turnover recorded at a value of 0.30.BioCryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.50.
Earnings per share (EPS) analysis for BioCryst Pharmaceuticals Inc. [BCRX] stock
With the latest financial reports released by the company, BioCryst Pharmaceuticals Inc. posted -0.02/share EPS, while the average EPS was predicted by analysts to be reported at -0.26/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 92.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioCryst Pharmaceuticals Inc. go to 19.90%.
BioCryst Pharmaceuticals Inc. [BCRX]: Insider Ownership positions
There are presently around $566 million, or 77.50% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: STATE STREET CORP with ownership of 16,183,973, which is approximately 3.887% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 15,943,893 shares of the stock with an approximate value of $70.95 million in BCRX stocks shares; and BAKER BROS. ADVISORS LP, currently with $56.5 million in BCRX stock with ownership of nearly -7.777% of the company’s market capitalization.
Positions in BioCryst Pharmaceuticals Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 85 institutional holders increased their position in BioCryst Pharmaceuticals Inc. [NASDAQ:BCRX] by around 14,582,604 shares. Additionally, 78 investors decreased positions by around 20,262,574 shares, while 23 investors held positions by with 92,254,294 shares. The mentioned changes placed institutional holdings at 127,099,472 shares, according to the latest SEC report filing. BCRX stock had 28 new institutional investments in for a total of 2,472,570 shares, while 31 institutional investors sold positions of 2,953,537 shares during the same period.